Yishan Chen

Yishan Chen

Auto-generated profile, based on publicly available information

Yishan Chen

Department of Sports Medicine of Second Affiliated Hospital, Liangzhu Laboratory, and Zhejiang University–University of Edinburgh Institute, Zhejiang University School of Medicine, Hangzhou, 310000, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
YCYishan Chen
Yishan Chen
WSWei Sun
Wei Sun
YWYa Wen
Ya Wen
XWXiaozhao Wang
Xiaozhao Wang
JLJiachen Li
Jiachen Li
HOHongwei Ouyang
Hongwei Ouyang
Osteoarthritis (OA) affects nearly 500 million people worldwide and is characterized by an irreversible loss of glycosaminoglycans (GAGs) at articular cartilage surfaces, which are essential in maintaining cartilage mechanical properties and chondrocyte phenotypes. Despite advances, preserving cartilage GAGs and controlling their turnover in living cells remain challenging. On the basis of the hypothesis that GAGs can interact with cationic molecules, we demonstrated a cost-effective strategy to increase human cartilage GAGs using a cationic polymer hexadimethrine bromide (HDMBr). HDMBr promoted chondrogenesis of mesenchymal stem cells by attracting pericellular GAGs and up-regulating vesicle formation, leading to increased matrix secretion. HDMBr also acted like a molecular assembler to promote the assembly of chondroitin sulfate (CS) into highly concentrated condensates during intracellular trafficking, resulting in more efficient GAG secretion. HDMBr was then evaluated as a potential therapeutic in two animal models. In a rabbit model of large cartilage defects, HDMBr promoted the intrinsic regeneration of GAG-rich hyaline-like cartilage and improved tissue integration. In a rat model of OA, low-dose HDMBr treatment increased cartilage thickness, supported cartilage matrix homeostasis, and supported cell-based therapy, reducing OA damage as compared with other tested clinical treatments. Overall, this study introduces a cost-effective GAG manipulation approach to cartilage repair and joint preservation, offering insights into the mechanisms of cell-material interactions.

13 September 2024 in Science Advances
Verified
Journal Article
Open access
YCYishan Chen
Yishan Chen
YYYiyang Yan
Yiyang Yan
RTRuonan Tian
Ruonan Tian
ZSZixuan Sheng
Zixuan Sheng
LLLiming Li
Liming Li
HOHongwei Ouyang
Hongwei Ouyang
The rapid advancement of cell therapies underscores the importance of understanding fundamental cellular attributes. Among these, cell fitness—how transplanted cells adapt to new microenvironments and maintain functional stability in vivo—is crucial. This study identifies a chemical compound, FPH2, that enhances the fitness of human chondrocytes and the repair of articular cartilage, which is typically nonregenerative. Through drug screening, FPH2 was shown to broadly improve cell performance, especially in maintaining chondrocyte phenotype and enhancing migration. Single-cell transcriptomics indicated that FPH2 induced a super-fit cell state. The mechanism primarily involves the inhibition of carnitine palmitoyl transferase I and the optimization of metabolic homeostasis. In animal models, FPH2-treated human chondrocytes substantially improved cartilage regeneration, demonstrating well-integrated tissue interfaces in rats. In addition, an acellular FPH2-loaded hydrogel proved effective in preventing the onset of osteoarthritis. This research provides a viable and safe method to enhance chondrocyte fitness, offering insights into the self-regulatory mechanisms of cell fitness.